Results 61 to 70 of about 28,144 (206)

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Apixaban for prevention of thromboembolism in pediatric heart disease

, 2023
Background: Children with heart disease frequently require anticoagulation for thromboprophylaxis. Current standard of care (SOC), vitamin K antagonists or low-molecular-weight heparin, has significant disadvantages.
Bu'Lock, Frances
core   +2 more sources

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

Clinical Pharmacology: Advances and Applications, 2013
Yimin Cui,1 Yan Song,2 Jessie Wang,2 Zhigang Yu,2 Alan Schuster,2 Yu Chen Barrett,2 Charles Frost2 1Peking University First Hospital, Beijing, People's Republic of China; 2Bristol-Myers Squibb, Princeton, NJ, USA Background: The pharmacokinetics (PK),
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C   +6 more
doaj  

Sustained resolution of anticoagulation related iron deficiency anemia with the use of apixaban

, 2019
Successful resolution of iron deficiency anemia in the context of anticoagulation with rivaroxaban was seen when apixaban is used alternatively.
Alghamry, Alaa, Siyaguna K. D. M. Ekanayake, Alaa Alghamry, Choo, Alex, Ekanayake, Siyaguna KDM, Alessia Bragagnolo, Bragagnolo, Alessia, Ekanayake, Siyaguna K. D. M., Alex Choo   +8 more
core   +1 more source

Do We Really Know How to Manage Anticoagulated Patients for Periodontal Nonsurgical Therapy? An Observational Cohort Study

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton, A. Rapani, F. Costantinides, V. Nicolin, D. Cuhureanu, R. Di Lenarda   +5 more
wiley   +1 more source

Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA2DS2‐VALa Score

Journal of Cardiovascular Electrophysiology, EarlyView.
In anticoagulated atrial fibrillation, residual ischemic stroke risk persists despite guideline‐directed therapy. In this single‐center cohort, an enlarged index outpatient left atrial diameter independently predicted stroke and improved risk stratification when added to CHA2DS2‐VA (CHA2DS2‐VALa), supporting a simple, clinically implementable ...
Sefa Erdi Ömür, Emin Koyun, Gülşen Genç Tapar, Kayıhan Karaman, Metin Karayakali, Ataç Çelik, Uğur Kulu, Yasin Taşkin   +7 more
wiley   +1 more source

Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement [PDF]

, 2017
Factor Xa inhibitors (FXaI) apixaban and rivaroxaban are used for thromboprophylaxis after major elective orthopaedic surgery. Because few patient sample studies exist, we postoperatively assessed patients undergoing unilateral total hip arthroplasty ...
Lassila, Riitta, Jarkko Leskinen, Lotta Joutsi-Korhonen, Joutsi-Korhonen, Lotta, Lauri Virtanen, Helin, Tuukka A., Riitta Lassila, Mikko Manninen, Leppilahti, Juhana, Tuukka A. Helin, Juhana Leppilahti, Virtanen, Lauri, Manninen, Mikko, Leskinen , Jarkko   +13 more
core   +1 more source

Early Bleeding Risk After DOAC Initiation With Concomitant Amiodarone in Older Adults With Atrial Fibrillation

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Amiodarone is frequently co‐prescribed with direct oral anticoagulants (DOACs) in atrial fibrillation (AF), but its impact on early bleeding risk after DOAC initiation in older adults remains uncertain. We evaluated short‐term safety outcomes associated with concomitant amiodarone use at the time of DOAC initiation.
Isadora D. Guarino, Saman Nazarian
wiley   +1 more source

Apixaban-induced leukocytoclastic vasculitis

, 2020
SummaryIntroduction:Drug-induced vasculitis is a rare adverse drug reaction and the potential to induce such a reaction is often established postmarketing.
Schmidt, Jakob Nøhr, Damkier, Per; id_orcid, Per Damkier, Peter Esbech, Esbech, Peter, Lone Kærslund Andersen, Jakob Nøhr Schmidt, Andersen, Lone Kærslund   +7 more
core   +1 more source